<DOC>
	<DOCNO>NCT02950857</DOCNO>
	<brief_summary>An open-label study 6 patient receive once-weekly subcutaneous injection EPEG 4 week . Final visit occur 60 day study entry</brief_summary>
	<brief_title>A Study EPEG Beta Thalassemia Patients</brief_title>
	<detailed_description>Following provision inform consent , screen visit procedure perform include : detailed medical history ( include concomitant medication ) , physical exam , vital sign ( non-invasive systolic diastolic arterial blood pressure , heart rate , respiratory rate , temperature , oxygen saturation pulse oximetry , ) , laboratory test blood sample collection safety ( hematology chemistry ) , urinalysis ( dipstick microscopy , necessary ) . A serum pregnancy test female patient ( child-bearing potential ) measure Screening Visit . Urine pregnancy test female patient ( child-bearing potential ) measure dose visit prior dose . Eligible patient receive either subcutaneous injection EPEG ( 0.9 µg/kg , 1.2 µg/kg , 1.5 µg/kg , ) four week follow follow 5-6 week 4th dose IP . Vital sign record study documentation 1 hour dose discharge day ( occur 2 hour time dose ) . All patient receive standard care per investigative site standard practice .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>1 . Male female 2 . Age 18 65 year age 3 . Confirmed diagnosis NonTransfusion Dependent βthalassemia ( βNTDT ) 4 . Hemoglobin 6.010.0 g/dL 5 . Signed date informed write consent subject 6 . Able receive subcutaneous injection study drug 7 . Female patient must nonlactating 8 . Female patient reproductive potential must negative serum pregnancy ( βHCG ) test screening . 1 . In judgment investigator patient good candidate study 2 . Blood transfusion within last 30 day 3 . Any following medical condition : 1 . Severe kidney insufficiency , define use hemodialysis serum creatinine level great 2.5 mg/dL time screen 2 . Cardiac disease adjustment cardiac medication 60 day study entry 3 . Symptomatic coronary artery disease , indicate history chest pain , angina , claudication , surgery treat coronary artery disease 1 year study entry 4 . Stroke , define new focal neurological deficit last 24 hour 45 day study entry 5 . New diagnosis pulmonary embolism ventilationperfusion scan , angiography , technique 90 day study entry 6 . History retinal detachment retinal hemorrhage 180 day study entry 7 . Use nitratebased vasodilator , prostacyclin ( inhale , subcutaneous , intravenous ) 8 . Acute asthma exacerbation require use prednisone 60 day study entry 9 . Initiation dosage increase calcium channel blocker 30 day study entry 10 . Initiation cardiac pulmonary medication 90 day study entry 4 . Presence condition , opinion investigator , would make person unsuitable enrollment could interfere compliance study , include limited alcohol drug abuse 5 . Any prior treatment Erythropoiesisstimulating Agents ( ESA ) within 90 day study treatment ; 6 . History hypersensitivity erythropoietin related drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>